Press release
Investigation for Long-Term Investors in shares of BioLineRx Ltd. (NASDAQ: BLRX) announced
An investigation on behalf of investors in BioLineRx Ltd. (NASDAQ: BLRX) shares over potential wrongdoing at BioLineRx Ltd.
Investors who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioLineRx Ltd. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Israel based BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd.
BioLineRx Ltd. reported that its Net Loss declined from $30.02 million in 2020 to $27.05 million in 2021.
Shares of BioLineRx Ltd. (NASDAQ: BLRX) declined from $3.15 per share on October 15, 2021, to as low as $0.76 per share on November 9, 2022.
Those who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Long-Term Investors in shares of BioLineRx Ltd. (NASDAQ: BLRX) announced here
News-ID: 2800511 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for BioLineRx
Pancreatic Beta Cell Protection Market Growth Expected to See Next Level: Sanofi …
The latest study released on the Global Pancreatic Beta Cell Protection Market by HTF MI Research evaluates market size, trend, and forecast to 2029. The Pancreatic Beta Cell Protection market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and…
Investigation announced for Long-Term Investors in BioLineRx Ltd. (NASDAQ: BLRX) …
An investigation was announced for current long-term investors in shares of BioLineRx Ltd. (NASDAQ: BLRX) concerning potential breaches of fiduciary duties by certain directors of BioLineRx Ltd.
Investors who are current long term investors in BioLineRx Ltd. (NASDAQ: BLRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: BLRX…
Lawsuit filed for Investors who lost mone with shares of BioLineRx Ltd. (NASDAQ: …
An investor, who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX), filed a lawsuit alleged violations of Federal Securities Laws by BioLineRx Ltd.
Investors who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 6, 2023. NASDAQ: BLRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Israel based BioLineRx Ltd., a clinical-stage biopharmaceutical development…
Celiac Disease Treatment Market Key Companies Amgen, BioLineRx, General Mills, Z …
The Global Celiac Disease Treatment Market 2019-2026 Industry is a disorder in which eating gluten triggers an immune response in the body, causing inflammation and damage to the small intestine. Rise in number of diabetes cases and increase in awareness of disease are propelling the market growth. However, limited availability of the treatment and misdiagnosis of celiac disease might restrain the market growth in the forecast period.
Buy one-Get one: …
Hematopoietic Stem Cell (HSC) Mobilization Therapeutics Pipeline Analysis | BioL …
Mobilization is the recruitment of hematopoietic stem cells (HSC) into peripheral blood from the bone marrow following chemotherapy treatment. There are several advantages for reinfusion of autologous mobilized peripheral blood stem cells over bone marrow HSC.
Download the sample report @ https://www.pharmaproff.com/request-sample/1134
Some of the major advantages include enhanced immune reconstitution, shorter duration of granulocytopenia, shorter hospital stays, reduced morbidity and mortality and saving of financial resources. Several factors, such as type…
Thrombocytopenia Management Market Analysis (2019 - 2025)| Amarillo Biosciences, …
In the recently published report, QY Research has provided a unique insight into the global Thrombocytopenia Management market for the forecasted period of 7-years (2018-2025). The report has covered the significant aspects that are contributing to the growth of the global Thrombocytopenia Management market. The primary objective of this report is to highlight the various key market dynamics such as drivers, trends, and restraints that are impacting the global Thrombocytopenia…
